7 November 2019

PRESS RELEASE – Novel ICI combination with aPD1 or aCTLA4
7 November 2019

– PRESS RELEASE – For immediate release   Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies   Lyon, France, November 7th, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, will showcase preclinical efficacy data of a novel regulator of response to anti-PD1 and anti-CTLA4 immunotherapies. “We are thrilled to share the data on this program”, commented Jeremy Bastid, Chief Operating Officer. “The target was identified as a master regulator of anti-PD1 and anti-CTLA4 response in resistant mouse models using our in vivo genetic screening platform”. Dr Bonnefoy further commented on the preclinical antibody data : “Similarly to the KO mice, the candidate mAb was shown to turn non-responders or partial responders to PD1 or CTLA4 targeting therapies into complete responders with long term survival in several mouse models. We have compelling evidence suggesting that the mechanism of action involves the reduction of myeloid cell infiltration as well as profound alterations in the tumor draining lymph nodes.” The data will be presented on November 9th, 2019 during the 34th SITC annual meeting held at the Gaylord National Hotel & Convention Center in National Harbor, MD, USA. The full abstract #P286 “In vivo genetic screens in PD-1 resistant mouse models identified modulator of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma” has now been released and is accessible online. The poster will be displayed on Saturday, November 9th, 7:00 am – 8:30 pm. Our team, Jeremy Bastid, Chief Operating Officer of OREGA Biotech and Nathalie Bonnefoy, acting Chief Scientific Officer, will be present during the poster sessions 12:35 – 2:05 pm and 7:00 – 8:30 pm to discuss the data and provide more information on the program. Download the press release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 and anti-CTLA4 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or […]
[ Read more ]
30 September 2019

PRESS RELEASE – Novel immune checkpoint presented at SITC 2019
30 September 2019

– PRESS RELEASE – For immediate release   First-in-class immune checkpoint inhibitor program presented by OREGA Biotech at SITC meeting Preclinical-stage blocking antibodies against a novel immune checkpoint; Increased response and survival to anti-PD1 in various PD1-resistant mouse models   Lyon, France, October 1st, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today the presentation of the preclinical data of its novel immune checkpoint program at the upcoming SITC meeting to be held November 6 -10, National Harbor, Maryland (USA). The company has built an in vivo screening platform combining a knock-out (KO) approach against selected targets and several PD1 and/or CTLA4 resistant syngeneic mouse models aiming at identifying novel immune checkpoints and modulators of anti-PD1 or CTLA4 response. Using this target discovery approach, OREGA has already successfully identified CD39 as a novel immune checkpoint and the anti CD39 program was licensed to Innate Pharma in 2016 and has been further partnered with AstraZeneca/MedImmune in 2018. At SITC, we present for the first time a novel immuno-oncology target which plays a key role in anti- PD1 resistance. Whereas the used mouse models are broadly resistant to anti-PD1 mAb, the target KO markedly improved the efficacy of anti-PD1 therapy by increasing the response rates and the rate of complete vs partial responses, which translated into improved mouse survival. We report the generation of various human-mouse cross-reactive blocking antibodies to the target. The neutralizing antibodies mimicked the KO phenotype and markedly improved the response to anti-PD1 therapy in the preclinical mouse models. Analyzing human metastatic melanoma tumors prior to pembrolizumab treatment, OREGA scientists found a stepwise increased expression of the target, its receptor and the signaling pathway from complete responders (low expression) to partial responders and non-responders (high expression), suggesting that the identified target is relevant to clinics. Dr. Nathalie Bonnefoy, Deputy Director at Institut de Recherche en Cancérologie de Montpellier and acting Chief Scientific Officer at OREGA Biotech, commented: “It is now well established that only patients achieving complete response to anti-PD1 are the ones that derive long-term survival benefit from these immunotherapies. We designed a program aiming at identifying targets that may turn PD1 resistant tumors into PD1 sensitive tumors, improve response to these therapies and promote long term survival. We report for the first time preclinical data related to this novel immuno-oncology program. These data represent long term […]
[ Read more ]
23 September 2019

Meet us at BIO-Europe 2019, Nov. 11 & 12
23 September 2019

OREGA Biotech – meet us at BIO-Europe 2019, Nov. 11 & 12  Lyon, France, September 23, 2019 – OREGA Biotech will participate in the upcoming BIO-Europe conference to be held in Hamburg, Germany, on November 11-13, 2019. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. OREGA Biotech will actively take part in this business event to promote our partnership-driven business model based on our in vivo screening platform aiming at discovering novel immune checkpoints and regulators of anti-PD1 response. Building on the successful partnering of our anti-CD39 antibodies (licensed to Innate Pharma and now partnered with AstraZeneca), we are open to discussion for our new program related to the discovery of a novel regulator of anti-PD1 response. Jeremy Bastid, Chief Operating Officer, will attend the BIO-Europe conference on November 11 & 12, 2019. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoints and regulators of anti-PD1 response. Anti-CD39 antibody were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with our targets prior entering into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO. For more information: www.orega-biotech.com  
[ Read more ]
17 September 2019

Dr Bonnefoy to inaugurate first CyTOF Hyperion in France
17 September 2019

Nathalie Bonnefoy, cofounder of OREGA Biotech and deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM), will inaugurate the first CyTOF Hyperion in France on September 18, 2019 at IRCM. Equipped with a very innovative technology, the CyTOF Hyperion will make it possible to explore tumor heterogeneity from a biopsy by very finely mapping tumor cells in their microenvironment, including the interactions with and between the immune cells. The CyTOF is a powerful tool for immuno-oncology studies. It reveals the structure of disease tissue at the single cell level and enables the characterization with up to 50 markers, from a single slide, of the spatial distribution and the cellular network with immune cells.
[ Read more ]